Plasmablastic lymphoma

Rubén Fernández-Álvarez, Juan Manuel Sancho, Josep María Ribera

Research output: Contribution to journalReview articleResearchpeer-review

3 Citations (Scopus)


© 2016 Elsevier España, S.L.U. Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of non-Hodgkin lymphoma that commonly occurs in human immunodeficiency virus (HIV)-positive individuals, and affects oral sites. Occasionally, it has been described in HIV-negative patients and involving non-oral sites. Pathologically, PBL is a high-grade B-cell lymphoma that displays the immunophenotype of a terminally differentiated B-lymphocyte with loss of B-cell markers (CD20) and expression of plasma-cell antigens. Epstein-Barr virus infection and MYC rearrangements are frequently observed. Treatment of PBL is challenging because of the lack of established treatment and poor outcomes, with median survival times shorter than one year. In this review, we discuss the clinical and epidemiologic spectrum of PBL as well as its distinct pathological features. Finally, we summarize the currently available approaches for the treatment of patients with PBL.
Original languageEnglish
Pages (from-to)399-404
JournalMedicina Clinica
Issue number9
Publication statusPublished - 4 Nov 2016


  • Bortezomib
  • Chemotherapy
  • Human immunodeficiency virus infection
  • MYC
  • Plasmablastic lymphoma

Fingerprint Dive into the research topics of 'Plasmablastic lymphoma'. Together they form a unique fingerprint.

Cite this